Crucell Announces PER.C6 and AdVac Technology License Agreement with Wyeth Pharmaceuticals
Crucell N.V. announced that it has entered into a co-exclusive PER.C6® and Advac® technology license agreement with Wyeth Pharmaceuticals, a division of Wyeth.
Under the terms of the agreement, Crucell will receive an upfront payment, milestone payments, annual maintenance fees, and royalties on net product sales. Other financial details were not disclosed.
Crucell's AdVac® technology is a recombinant vector technology used to develop novel adenoviral-based products. PER.C6® technology is based on a human cell line developed for the large-scale manufacture of biological products including vaccines.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.